Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been confirmed by laboratory testing (tissue or cell samples) to have advanced solid tumours or Hodgkin's or Non-Hodgkin's lymphoma that has come back or stopped responding to treatment — this includes cancers such as bowel, head and neck, liver, lung, stomach, ovarian, kidney, skin (melanoma), bile duct cancers, certain sarcomas, and several types of lymphoma, among others
• People whose cancer can be measured on scans — for solid tumours, at least one tumour measuring 10 mm or more; for lymphomas, at least one lesion measuring more than 15 mm, visible on specific types of scans
• People whose tumour has certain molecular features (such as high immune cell activity, high number of gene changes, or specific gene mutations) — these patients will be given priority for enrolment (confirm with trial site)
• People who can provide a tumour tissue sample, either from stored laboratory blocks, prepared slides, or a fresh biopsy taken before starting the trial treatment
• People with tumours that can be safely biopsied who are willing to have an additional biopsy during the trial as scheduled
• People with a general health and activity level rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
• People whose doctor estimates they have a life expectancy of at least 3 months
• People who have recovered from most side effects of previous cancer treatments before starting this trial (minor ongoing side effects such as hair loss, mild nerve symptoms, hearing loss, or hormone conditions managed with medication may be acceptable)
• People whose blood counts, kidney, liver, and heart function meet the minimum levels required by the trial (as measured by standard blood and heart tests)
• People who agree to use effective contraception from the screening period through to 4 months after the last dose of trial treatment, and who have no plans to conceive during this time — this applies to all participants and their partners
• People who are willing and able to give written informed consent to take part

Who may not be able to join:

• People with a known allergy to any ingredient in the trial treatment (JLM019)
• People who have previously had a severe (Grade 4) allergic or infusion reaction to any monoclonal antibody or similar protein-based therapy
• People who experienced a serious heart-related immune side effect, or who had to stop a previous immunotherapy due to a severe (Grade 3 or higher) immune-related side effect
• People who have an active infection currently requiring intravenous antibiotics or antifungal treatment, or who have an unexplained fever
• People who have had a serious blood vessel or heart event in the past 6 months, such as a heart attack, unstable chest pain, stroke, or disease of the large blood vessels
• People with blood pressure that remains very high (160/100 mmHg or above) despite treatment
• People with active blood clots, active bleeding, or conditions that significantly increase bleeding risk
• People with an active autoimmune disease that currently requires systemic medication (such as steroids or immune-suppressing drugs) — hormone replacement therapies are generally not considered in this category
• People with any serious or uncontrolled heart condition, including any history of heart muscle inflammation (myocarditis), severe heart failure, recent heart attack or stroke, poor heart pumping function (below 45% on an ultrasound), or significant abnormal heart rhythm findings on a heart tracing — some exceptions may be possible after review by a heart specialist and approval by the trial sponsor (confirm with trial site)
• People who have a history of, or currently have, lung inflammation not caused by infection (pneumonitis or interstitial lung disease)
• People with active cancer that has spread to the brain or the lining of the brain or spinal cord — solid tumour patients who have already received treatment for brain metastases and whose scans show no sign of growth for at least 8 weeks may potentially still be considered (confirm with trial site)
• People who have previously received an organ transplant or a bone marrow/stem cell transplant from another person — lymphoma patients who are at least 3 months past a stem cell transplant with no active graft-versus-host disease may potentially be considered with approval (confirm with trial site)
• People who have received certain recent cancer treatments within specified time periods before starting the trial, including immunotherapy checkpoint inhibitors (within 3–4.5 months), chemotherapy or targeted therapy or radiotherapy (within 2 weeks), or other antibody-based or cell-based therapies (within 4 weeks)
• People who are currently in, or have recently completed, another clinical trial within the past 4 weeks
• People who have needed regular steroid medication (above a low dose) or other immune-suppressing drugs in the 14 days before starting the trial — inhaled, nasal spray, or skin-applied steroids are generally acceptable
• People who have received a live or live-weakened vaccine within 30 days before starting the trial (inactivated vaccines are generally allowed)
• People who have had radiotherapy within 2 weeks of starting the trial, or who have a history of radiation-related lung inflammation
• People who have had another active cancer within the past 3 years — some exceptions may apply for certain early-stage or skin cancers that have been fully treated (confirm with trial site)
• People with a history of HIV/AIDS, syphilis, or active hepatitis B or C (based on specific blood test results)
• People who are pregnant or breastfeeding, or people of childbearing potential who have a positive pregnancy test within 7 days before starting treatment
• People the trial investigator considers unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.